[Present status and future prospects in reduced intensity stem cell transplantation].
Takaue
Yoichi
Y
D000970:Antineoplastic Agents / Q000008:administration & dosage; D006086:Graft vs Host Disease / Q000276:immunology / Q000517:prevention & control; D020544:Graft vs Leukemia Effect; D006680:HLA Antigens; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods / Q000639:trends; D006648:Histocompatibility; D006801:Humans; D007938:Leukemia / Q000628:therapy; D017710:Lymphocyte Transfusion; D015778:Minor Histocompatibility Antigens; D009369:Neoplasms / Q000628:therapy; D014019:Tissue Donors; D019172:Transplantation Conditioning / Q000379:methods / Q000639:trends; D014181:Transplantation Immunology
D000970:Antineoplastic Agents; D006680:HLA Antigens; D015778:Minor Histocompatibility Antigens